SRPT Price Target - ETF Channel

The median SRPT price target (a different metric than the average or mean) was $197.0 as of 2025-01-10, the highest SRPT price target in the range was $217.0 while the lowest SRPT price target in the range was $75.0, with a standard deviation of $32.031. Get the latest Zacks …

$197
OFF

SRPT Price Target - ETF Channel

2 weeks from now

etfchannel.com

$126.29
OFF

Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target …

2 weeks from now

Jan 4, 2025 · SRPT opened at $126.29 on Wednesday. The company has a market cap of $12.06 billion, a P/E ratio of 101.03 and a beta of 0.77. The company has a fifty day moving average …

etfdailynews.com

$75.00
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Analyst Ratings, Price ...

2 weeks from now

The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by HC Wainwright & Co. on December 19, 2024. The analyst firm set a price target for $75.00 expecting SRPT to …

benzinga.com

$90
OFF

SRPT: Average Analyst Price Target Is $90 - StockNews

2 weeks from now

68 rows · Best ETF Categories High Yield ETFs 7 Best ETFs ... SRPT's average price target has moved down $29.16 over the prior 34 weeks. Over the past 50 weeks, SRPT's average upside …

stocknews.com

$152.00
OFF

Summary - SRPT - NASDAQ - Weiss Ratings

2 weeks from now

Jan 6, 2025 · 12/31/2024 - ETF Channel. Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? 12/29/2024 ... SRPT) Price Target to $152.00 …

weissratings.com

$217
OFF

Sarepta Price Target Raised To $217 From $210 At BofA - Nasdaq

2 weeks from now

Nov 26, 2024 · BofA analyst Tazeen Ahmad raised the firm’s price target on Sarepta (SRPT) to $217 from $210 and keeps a Buy rating on the shares after the company announced an …

nasdaq.com

$161.00
OFF

Sarepta Therapeutics Reaches Analyst Target Price - Nasdaq

2 weeks from now

Jun 25, 2024 · In recent trading, shares of Sarepta Therapeutics Inc (Symbol: SRPT) have crossed above the average analyst 12-month target price of $161.00, changing hands for …

nasdaq.com

$150
OFF

Sarepta Price Target Raised To $150 From $148 At Guggenheim

2 weeks from now

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

nasdaq.com

$170.69
OFF

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

2 weeks from now

35 analysts have given Sarepta Therapeutics (SRPT) a consensus rating of Buy while the Sarepta Therapeutics (SRPT) price prediction in 2025 is $170.69

public.com

$179.00
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating At HC

2 weeks from now

18 hours ago · Evercore ISI dropped their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a report on Thursday, …

marketbeat.com

$203.00
OFF

Strong Financial Performance And Strategic Growth ... - Markets …

2 weeks from now

1 day ago · Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $203.00 price target. Stay Ahead of the Market: Discover outperforming stocks and invest …

businessinsider.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Going by the price/sales ratio, the stock currently trades at 7.73, trailing 12-month sales value, higher than 1.96 for the industry. Image Source: Zacks Investment Research

nasdaq.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell? - Yahoo …

2 weeks from now

Jan 6, 2025 · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

yahoo.com

FAQs about SRPT Price Target - ETF Channel Coupon?

Where can I buy SRPT stock?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? ...

Is Sarepta Therapeutics a good stock to buy?

5.85% of the outstanding shares of Sarepta Therapeutics have been sold short. Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.8. Short interest in Sarepta Therapeutics has recently decreased by 3.95%, indicating that investor sentiment is improving. Sarepta Therapeutics does not currently pay a dividend. ...

Is Sarepta a good investment?

The consistent growth in Elevidys revenue, driven by increased patient dosing, particularly among non-ambulant patients, further supports the Buy rating. This combination of robust current performance and promising future prospects makes Sarepta an attractive investment, according to Baral. ...